Abstract: Hirudin derivatives can be prepared by the selective enzymic replacement of a part of the molecule with an amino derivative. The hirudin derivatives are suitable for preparing pharmaceuticals having an anticoagulatory effect.

Abstract: Phosphoinositol-glycan-peptide with insulin-like actionPhosphoinositol-glycan-peptides obtainable by cleavage of adenosine 3',5'-cyclic monophosphate-binding protein, which contain glucosamine, galactose, mannose, inositol, phosphoric acid, ethanolamine and a peptide with the sequence Asx-Cys-Tyr, the preparation and use thereof for the treatment of diabetes mellitus and non-insulin-dependent diabetes are described.

Abstract: The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.

Abstract: The present invention relates to hirudin derivatives which are formed from hirudin or the physiologically acceptable salt thereof and a carrier, to a process for the preparation thereof, and to the use thereof as thrombin inhibitor.

Abstract: Thrombin inhibitors from the hirudin family which differ from the previously known hirudins by mutation in the protein chain, and a process for their preparation are described. The novel hirudins are distinguished by a high specific activity, high stability and good pharmacokinetics.

Abstract: Novel synthetic isohirudins with improved stability The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.

Abstract: The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.

Abstract: A hirudin derivative which has the N-terminal amino acid sequence Leu-Thr-Tyr-Thr-Asp shows high biological activity. Moreover, this hirudin derivative can be obtained very efficiently by genetic engineering preparation in yeasts.

Abstract: A new transaminase has been isolated from E. coli DH-1 (ATCC 33849). It is possible to use the transaminase with great efficiency to prepare L-phosphinothricin and gamma-aminobutyric acid from appropriate precursors by transferring an amino group from glutamate.

Abstract: A process for the preparation of a purified transaminase having a molecular weight of 20,000 to 250,000 daltons, an isoelectric point at a pH between 3.0 and 8.0, a pH optimum in a range from 5.0 to 10.0 and a substrate specificity for the transamination of (3-carboxy-3-oxo-propyl)-methyl-phosphinic acid or the esters thereof.The production of the enzyme comprises cultivating E. coli ATCC 33849, disrupting the cultivated E. coli ATCC 33849, obtaining a supernatant therefrom containing the enzyme and isolating the transaminase by heating the supernatant at a temperature and for a time sufficient to denature proteins other than the transaminase and than finally removing the denatured proteins from the supernatant.

Abstract: The invention relates to a process for the isolation and purification of hirudin from complex and salt-containing solutions by hydrophobic chromatography, using as stationary phase porous adsorber resins and as mobile phase organic solvents which are miscible with water.

Abstract: The invention relates to a new active substance--amblyommin--for anticoagulant therapy and to a process for the isolation thereof from hard ticks. The isolated protein having a thrombin-inhibitory action has a molecular weight of 20000 to 30000 dalton, an isoelectric point between 5.05 and 5.65 and the partial amino acid sequencesIle-Leu-Phe-Thr-Gln-Gly-Asn-X-Gly-Glu-Leu-Glu-Asn-X-Phe-Glu-,Lys-Ile-Leu-Phe-X-Gln-Gly- andAla-Ser-Tyr-Ile-Val-X-Ser-Glu-Ser-Ile-Gln-Ile-Leu-X-Leu-Ser-Glu-Gly-Ile-in which each radical X can be identical or different and each represents a naturally occurring amino acid.

Abstract: The invention relates to a polypeptide of the formula ##STR1## in which R represents phenoloic hydrogen or a phenolic ester group and m, n, X, Z, A, B, C, D, E, F, G, I and J have the meanings given, and in which the 6 Cys radicals are linked in pairs via disulfide bridges, processes for the preparation or isolation thereof, their use and agents containing them.

Abstract: A protein or a pharmaceutically acceptable salt thereof. The protein has a molecular weight of 10,000-30,000 Dalton, an isoelectric point greater than 9.5, and an N terminus of the sequence H-Lys-X-Phe-Lys-Val-Asp-Val-Leu-Ala-Ala-Leu-X-Phe-Asn-Ala-, wherein X is an amino acid or a tryptic cleavage product which has the sequence -Gly-Ala-Asn-Ala-Val-Asn-. Methods for the isolation and purification of the protein, compositions containing the protein, and methods for the use of the protein and compositions, are also disclosed.

Abstract: The invention relates to polypeptides of the formula I ##STR1## in which m denotes 0-50, n denotes 0-100 and R denotes the phenolic hydrogen or a phenol ester group, X represents identical or different residues of naturally occurring .alpha.-amino acids, Y denotes Val, Ile, Thr, Leu or Phe, and Z represents identical or different residues of naturally occurring .alpha.-amino acids, and in which the Cys residues are linked pairwise via disulfide bridges, to a process for preparing or obtaining them and to agents containing them.

Abstract: Cyclic polypeptides of the formula I ##STR1## in which Z, S, Y and AS have the meanings given, a process for their preparation and their use are described. The compounds have an .alpha.-amylase-inhibiting action.

Abstract: The invention relates to a polypeptide which can be isolated from thymus glands and has an action on the immunological system, and which has a molecular weight of 3,480, a UV absorption with a maximum at 205 to 210 nm and an isoelectric point of 3.95+0.15 and a specific aminoacid composition, the N-terminal, if appropriate, carrying an acyl group or an acylglycyl group, processes for its isolation and purification, its use, agents containing this polypeptide, and its cleavage products, their use and agents containing them.

Abstract: The invention relates to a polypeptide which can be isolated from thymus glands and has an action on the immunological system, and which has a molecular weight of 3,480, a UV absorption with a maximum at 205 to 210 nm and an isoelectric point of 3.95+0.15 and a specific aminoacid composition, the N-terminal, if appropriate, carrying an acyl group or an acylglycyl group, processes for its isolation and purification, its use, agents containing this polypeptide, and its cleavage products, their use and agents containing them.